Frank Malinoski MD, PhD
Chief Medical Officer
Dr. Malinouski has extensive, over twenty years of vaccine experience in preclinical, clinical, regulatory, medical affairs (post-licensure), safety, and business development, including board membership. He received a BA degree from Colby College in 1976 and trained in microbiology (PhD; Rutgers University, 1981) and medicine (MD; Albany Medical College, 1985).
Throughout his career he held numerous executive positions such as Director of Clinical Research at Lederle-Praxis Biologicals, Senior Vice President of Clinical and Medical Affairs at Nabi Biopharmaceuticals, Vice President of Medical Affairs at Wyeth, Chief Medical Officer and Senior Vice President of Development for Oxxon Therapeutics, Inc, and Vice President and then Senior Vice President of Medical and Scientific Affairs at MedImmune, LLC. He served on the board of LigoCyte Pharmaceuticals, Inc., a biotech vaccine company in Bozeman, MT from March 2008 to March 2009 and is involved with the North Carolina Biotechnology Center in Wilmington, NC. Dr. Malinoski has authored or co-authored multiple scientific and vaccine related publications, and is a member of several editorial boards.